T1	Condition 0 25	Major depressive disorder
T2	Scope 31 49	psychotic features
R1	Has_scope Arg1:T1 Arg2:T2	
T3	Condition 51 79	Traumatic Brain Injury (TBI)
T4	Condition 93 129	impact on activities of daily living
R2	AND Arg1:T3 Arg2:T4	
T5	Condition 131 150	Developmental delay
T6	Condition 152 172	intellectual deficit
T7	Condition 182 210	evere educational disability
T8	Condition 229 270	dependence for activities of daily living
*	OR T7 T6 T5
T9	Scope 131 210	Developmental delay, intellectual deficit, and/or severe educational disability
R3	AND Arg1:T9 Arg2:T8	
T10	Condition 280 302	substance use disorder
T11	Temporal 272 279	Ongoing
R4	Has_temporal Arg1:T10 Arg2:T11	
T12	Condition 320 356	impact on activities of daily living
R5	AND Arg1:T10 Arg2:T12	
T13	Non-query-able 358 474	Difficult or impossible to determine whether cognitive or functional decline is due to substance use or HIV, or both
T14	Condition 488 500	intoxication
T15	Condition 504 514	withdrawal
*	OR T15 T14
T16	Condition 548 587	Central nervous system (CNS) infections
T17	Condition 548 576;591 615	Central nervous system (CNS) opportunistic conditions
*	OR T17 T16
T18	Condition 617 630	brain abscess
T19	Condition 681 691	meningitis
T20	Condition 708 729	neurologic impairment
T21	Multiplier 697 707	persistent
R6	Has_multiplier Arg1:T20 Arg2:T21	
R7	AND Arg1:T19 Arg2:T20	
T22	Qualifier 632 641	bacterial
T23	Qualifier 643 656	mycobacterial
T24	Qualifier 658 664	fungal
T25	Qualifier 668 678	Toxoplasma
*	OR T25 T24 T23 T22
T26	Scope 632 678	bacterial, mycobacterial, fungal or Toxoplasma
R8	Has_scope Arg1:T18 Arg2:T26	
T27	Condition 739 751	CNS lymphoma
T28	Condition 753 801	progressive multifocal leukoencephalopathy (PML)
T29	Qualifier 806 813	another
T30	Condition 814 837	structural brain lesion
T31	Condition 843 864	neurological sequelae
R9	AND Arg1:T30 Arg2:T31	
R10	Has_qualifier Arg1:T30 Arg2:T29	
*	OR T30 T28 T27 T18 T19
T32	Scope 617 864	brain abscess (bacterial, mycobacterial, fungal or Toxoplasma), meningitis with persistent neurologic impairment, primary CNS lymphoma, progressive multifocal leukoencephalopathy (PML), or another structural brain lesion with neurological sequelae
T33	Scope 548 615	Central nervous system (CNS) infections or opportunistic conditions
R11	Subsumes Arg1:T33 Arg2:T32	
T34	Qualifier 866 871	Other
T35	Condition 872 886	CNS conditions
R12	Has_qualifier Arg1:T35 Arg2:T34	
T36	Qualifier 888 905	non-opportunistic
T37	Qualifier 906 913	primary
T38	Qualifier 731 738	primary
R13	Has_qualifier Arg1:T27 Arg2:T38	
T39	Qualifier 917 927	metastatic
T40	Condition 928 940	brain tumors
*	OR T39 T37
T41	Scope 906 927	primary or metastatic
R14	Has_scope Arg1:T40 Arg2:T41	
R15	Has_qualifier Arg1:T40 Arg2:T36	
T42	Qualifier 942 954	uncontrolled
T43	Condition 955 971	seizure disorder
R16	Has_qualifier Arg1:T43 Arg2:T42	
T44	Condition 973 1003	progressive multiple sclerosis
T45	Condition 1005 1011	stroke
T46	Condition 1017 1038	neurological sequelae
T47	Condition 1043 1051	dementia
T48	Negation 1066 1076	other than
T49	Condition 1077 1080	HIV
R17	Has_negation Arg1:T49 Arg2:T48	
T50	Condition 1086 1105	Alzheimer's disease
T51	Scope 1066 1080	other than HIV
R18	Subsumes Arg1:T51 Arg2:T50	
R19	Has_scope Arg1:T47 Arg2:T51	
R20	AND Arg1:T45 Arg2:T46	
*	OR T47 T45 T44 T43 T40
T52	Scope 888 1106	non-opportunistic primary or metastatic brain tumors, uncontrolled seizure disorder, progressive multiple sclerosis, stroke with neurological sequelae, or dementia due to causes other than HIV (eg, Alzheimer's disease)
T53	Scope 866 886	Other CNS conditions
R21	Subsumes Arg1:T53 Arg2:T52	
T54	Condition 1108 1130	Constitutional illness
T55	Condition 1147 1164	unexplained fever
T56	Multiplier 1136 1146	persistent
R22	Has_multiplier Arg1:T55 Arg2:T56	
T57	Condition 1166 1174	diarrhea
T58	Qualifier 1176 1187	significant
T59	Condition 1188 1199	weight loss
R23	Has_qualifier Arg1:T59 Arg2:T58	
T60	Condition 1201 1219	disabling weakness
*	OR T60 T59 T57 T55
T61	Scope 1136 1219	persistent unexplained fever, diarrhea, significant weight loss, disabling weakness
R24	Subsumes Arg1:T54 Arg2:T61	
T62	Temporal 1221 1248	within 30 days of screening
R25	Has_temporal Arg1:T54 Arg2:T62	
T63	Qualifier 1256 1265	untreated
T64	Condition 1266 1280	B12 deficiency
T65	Condition 1284 1296	malnutrition
*	OR T65 T64
T66	Measurement 1298 1319	body mass index [BMI]
T67	Value 1320 1332	less than 18
R26	Has_value Arg1:T66 Arg2:T67	
T68	Temporal 1334 1346	at screening
R27	Subsumes Arg1:T65 Arg2:T66	
T69	Scope 1266 1333	B12 deficiency or malnutrition (body mass index [BMI] less than 18)
R28	Has_qualifier Arg1:T69 Arg2:T63	
R29	Has_temporal Arg1:T69 Arg2:T68	
T70	Temporal 1360 1367	current
T71	Condition 1368 1401	hepatitis C virus infection (HCV)
T72	Measurement 1407 1424	HCV antibody [Ab]
T73	Value 1425 1433	positive
T74	Mood 1348 1356	Evidence
T75	Temporal 1434 1469	within 90 days prior to study entry
T76	Measurement 1494 1508	plasma HCV RNA
T77	Value 1509 1517	negative
R30	Has_value Arg1:T76 Arg2:T77	
R31	Has_value Arg1:T72 Arg2:T73	
R32	Has_temporal Arg1:T72 Arg2:T75	
T78	Temporal 1518 1545	within the same time period
R33	Has_temporal Arg1:T76 Arg2:T78	
*	OR T72 T76
T79	Scope 1407 1545	HCV antibody [Ab] positive within 90 days prior to study entry unless also shown to be plasma HCV RNA negative within the same time period
R34	Has_temporal Arg1:T71 Arg2:T70	
R35	Has_mood Arg1:T71 Arg2:T74	
R36	Subsumes Arg1:T71 Arg2:T79	
T80	Qualifier 1548 1556	Unstable
T81	Qualifier 1561 1569	advanced
T82	Condition 1570 1583	liver disease
R37	Has_qualifier Arg1:T82 Arg2:T81	
R38	Has_qualifier Arg1:T82 Arg2:T80	
T83	Multiplier 1615 1627	at least one
T84	Condition 1646 1653	ascites
T85	Condition 1655 1669	encephalopathy
T86	Condition 1671 1683	coagulopathy
T87	Condition 1685 1700	hypoalbuminemia
T88	Condition 1702 1712;1724 1731	esophageal varices
T89	Condition 1716 1731	gastric varices
T90	Qualifier 1736 1746	persistent
T91	Condition 1747 1755	jaundice
R39	Has_qualifier Arg1:T91 Arg2:T90	
*	OR T91 T88 T89 T87 T86 T85 T84
T92	Scope 1646 1755	ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
R40	Has_multiplier Arg1:T92 Arg2:T83	
T93	Scope 1615 1755	at least one of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
R41	Subsumes Arg1:T82 Arg2:T93	
T94	Temporal 1758 1763	Prior
T95	Temporal 1767 1774	current
*	OR T95 T94
T96	Drug 1786 1801	CCR5 antagonist
T97	Drug 1811 1814	MVC
T98	Drug 1819 1837	cenicriviroc [CVC]
*	OR T98 T97
T99	Scope 1811 1837	MVC and cenicriviroc [CVC]
R42	Subsumes Arg1:T96 Arg2:T99	
T100	Drug 1843 1862	integrase inhibitor
T101	Drug 1872 1875	RAL
T102	Drug 1877 1880	DTG
T103	Drug 1886 1904	elvitegravir [EVG]
*	OR T102 T101 T103
T104	Scope 1872 1904	RAL, DTG, and elvitegravir [EVG]
R43	Subsumes Arg1:T100 Arg2:T104	
*	OR T100 T96
T105	Scope 1786 1905	CCR5 antagonist (such as MVC and cenicriviroc [CVC]) and integrase inhibitor (such as RAL, DTG, and elvitegravir [EVG])
T106	Scope 1758 1774	Prior or current
R44	Has_scope Arg1:T105 Arg2:T106	
T108	Observation 2076 2089	Breastfeeding
T109	Condition 2106 2143	AIDS-defining opportunistic infection
T110	Temporal 2144 2174	within 6 months prior to entry
R45	Has_temporal Arg1:T109 Arg2:T110	
T111	Temporal 2286 2292	Active
T112	Condition 2293 2301	syphilis
T113	Procedure 2305 2314	treatment
T114	Condition 2319 2327	syphilis
R46	AND Arg1:T113 Arg2:T114	
*	OR T113 T112
R47	Has_temporal Arg1:T112 Arg2:T111	
T115	Temporal 2328 2363	within 90 days prior to study entry
R48	Has_temporal Arg1:T113 Arg2:T115	
T116	Reference_point 2352 2363	study entry
R49	Has_index Arg1:T115 Arg2:T116	
T117	Temporal 2371 2377	Active
T118	Condition 2378 2386	syphilis
R50	Has_temporal Arg1:T118 Arg2:T117	
T119	Value 2401 2419	four-fold increase
T120	Measurement 2423 2454	serum rapid plasma reagin (RPR)
T121	Measurement 2458 2501	venereal disease research laboratory (VDRL)
T122	Condition 2535 2543	syphilis
T123	Temporal 2530 2534	past
R51	Has_temporal Arg1:T122 Arg2:T123	
T124	Value 2554 2562	reactive
T125	Temporal 2548 2553	newly
T126	Measurement 2563 2572	serum RPR
T127	Measurement 2576 2580	VDRL
T128	Procedure 2588 2614	reactive confirmatory test
T129	Procedure 2616 2641	enzyme immunoassays [EIA]
T130	Procedure 2645 2673	chemiluminescent assay [CIA]
T131	Procedure 2675 2717	T. pallidum particle agglutination [TP-PA]
T132	Procedure 2722 2772	fluorescent treponemal antibody absorbed [FTA-ABS]
*	OR T132 T131 T130 T129
T133	Scope 2616 2772	enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS]
R52	Subsumes Arg1:T128 Arg2:T133	
*	OR T127 T126
R53	Has_temporal Arg1:T124 Arg2:T125	
T134	Scope 2563 2580	serum RPR or VDRL
R54	Has_value Arg1:T134 Arg2:T124	
*	OR T121 T120
T135	Scope 2423 2501	serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL)
R55	Has_value Arg1:T135 Arg2:T119	
T136	Scope 2401 2543	four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis
T137	Scope 2548 2773	newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])
*	OR T136 T137
T138	Scope 2401 2773	four-fold increase in serum rapid plasma reagin (RPR) or venereal disease research laboratory (VDRL) tests in an individual with past syphilis, or newly reactive serum RPR or VDRL with a reactive confirmatory test (enzyme immunoassays [EIA] or chemiluminescent assay [CIA], T. pallidum particle agglutination [TP-PA], or fluorescent treponemal antibody absorbed [FTA-ABS])
R56	Subsumes Arg1:T118 Arg2:T138	
T139	Condition 2782 2789	allergy
T140	Condition 2790 2801	sensitivity
*	OR T140 T139 T141
T141	Condition 2809 2825	hypersensitivity
T142	Drug 2829 2854	components of study drugs
T143	Scope 2782 2825	allergy/sensitivity or any hypersensitivity
R57	AND Arg1:T143 Arg2:T142	
T107	Drug 1926 1936	medication
T144	Drug 1948 1963	antiretrovirals
T145	Qualifier 1965 1988	prohibited in the study
R58	Subsumes Arg1:T107 Arg2:T144	
R59	Has_qualifier Arg1:T107 Arg2:T145	
T146	Temporal 1907 1914	Current
R60	Has_temporal Arg1:T107 Arg2:T146	
